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Closed loop control for type 1 diabetes
Shows promise in a research setting, but needs further development in practice
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In the linked randomised crossover studies (doi:10.1136/bmj.
d1855),Hovorkaandcolleaguescomparethesafetyandefficacy
of overnight closed loop insulin delivery with conventional
insulinpumpsinadultswithtype1diabetes.
1Automatedclosed
loopcontrol,knownasan“artificialpancreas,”hasthepotential
to greatly improve the health and lives of people with type 1
diabetes. The idea is not new—it can be traced back to
developments that took place decades ago, when studies using
intravenous glucose measurement and infusion of insulin and
glucose showed that external blood glucose regulation was
possible.
2 3Althoughthesesystemsresultedinexcellentglucose
control, they were cumbersome and unsuitable for long term or
outpatient use.
4 5
Withtheadventofminimallyinvasivesubcutaneouscontinuous
glucose monitoring, research and drug company efforts have
been focused on the development of subcutaneous artificial
pancreas systems. These systems link a continuous glucose
monitorandasubcutaneousinsulininfusionpumpviaacontrol
algorithm, which retrieves continuous glucose monitoring data
in real time (for example, every five minutes) and uses a
mathematicalformulatocomputeinsulindeliveryratesthatare
then transmitted to the insulin pump.
6 So far, several studies
have reported encouraging results.
7-10 Almost all of the studies
reportedthatclosedloopcontrolwasbetterthanstandardinsulin
infusion pump treatment in terms of three outcomes: increased
timewithinatargetrange,reducedincidenceofhypoglycaemia,
and better overnight control.
Hovorka and colleagues report two randomised crossover
clinical trials that looked at 24 adults with type 1 diabetes to
comparethesafetyandefficacyofovernightclosedloopinsulin
delivery with that of conventional insulin pump therapy. The
two protocols used a medium sized meal (60 g carbohydrate)
or a large size meal (100 g carbohydrate plus alcohol). As in
previous studies, closed loop insulin delivery significantly
increased the time that plasma glucose was in the target range
(3.91-8.0 mmol/L). In the context of ongoing research these
trials have several new features:
Firstly,therandomisedcrossovertrialdesignisvirtuallyunique
in the field of closed loop control. Because this design is the
gold standard for clinical research, the results set a benchmark
for future studies. The only other randomised controlled trial
of closed loop control was recently presented at the 4th
International Conference on Advanced Technologies and
Treatments for Diabetes.
11 This study recruited 24 adults and
adolescents with type 1 diabetes in the United States and in
FranceandachievedresultssimilartothosereportedbyHovorka
and colleagues—more time within the target range of 3.9-10
mmol/L and a threefold reduction in hypoglycaemia.
Secondly,thecontrolalgorithmusedbyHovorkaandcolleagues
belongstoanadvancedclassofclosedloopcontroltechnologies
knownasmodelpredictivecontrol.Algorithmdesignsforclosed
loop control have generally used either
proportional-integral-derivative control
6 7 or model predictive
control.
8-10 Proportional-integral-derivative control algorithms
are reactive, responding to changes in glucose levels with
adjustment in insulin delivery. Model predictive control
algorithms are built over a model of the human metabolic
system.Suchalgorithmsarethereforeproactiveandinsulincan
bedeliveredinanticipationofchangesinglucoseconcentrations.
This compensates partially for the time delays inherent in
subcutaneous glucose control (the time delay in insulin action,
which can amount to 60 minutes or more). For this reason,
model predictive control has become the approach of choice
more recently. The algorithm developed by Hovorka and
colleagues has certain distinct features, such as real time
adaptation of the underlying model to changing patient
parameters implemented as a selection from several predefined
models. However, because details have not been given in this
or in previous publications,
8 this potential advantage remains
to be evaluated.
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scenariosandchallengetheparticipantswithalargedinnerthat
included alcohol. As such, the study is a clear advance in the
quest for an ambulatory artificial pancreas.
However,astheauthorsadmit,onelimitationistheexclusively
manual control of the closed loop control system. The closed
loop control system relied on study personnel to transmit data
manually from the continuous glucose monitor to the computer
runningtheclosedloopcontrol,andtotransmitinsulininjection
recommendations from the computer to the insulin pump. In
fully automated systems these processes are handled by data
transmission and pump control devices, respectively. The
authors used manual control in their previous trials for well
knownreasons,includingtechnologicalandregulatorybarriers.
8
However, manual transfer of continuous glucose monitoring
dataandmanualcontroloftheinsulinpumpplacehumanfactors
into the closed loop control system and limit the investigation
totestingonlythecontrolalgorithm,nottheclosedloopcontrol
system as a whole. The testing of other key components, such
as sensor-pump communication and error mitigation, would
require much more effort and thorough system validation.
Studies using fully automated systems have already been
reported and offer hope for the future of ambulatory systems.
6-12
Finally, despite the sophistication of the control algorithm and
the significant reduction in nocturnal hypoglycaemia, four
episodes of severe hypoglycaemia (<3mmol/L) occurred, three
of which the authors thought were attributable to the preceding
prandial insulin dose and could not be prevented by the closed
loop suspending insulin delivery. This finding reinforces the
recently proposed idea that a dedicated hypoglycaemia safety
system—a separate algorithm responsible solely for the
assessment and mitigation of the risk of hypoglycaemia—may
need to accompany closed loop control.
12 Such safety systems
already exist, and have proved useful.
11 12
Inconclusion,closedloopcontrolisinitsinfancy,withthefirst
in-clinic studies now being reported. Preliminary results have
beenpromising—themostnotableimprovementisinovernight
control of type 1 diabetes, with improvements in safety and a
reduction in nocturnal hypoglycaemia being reported. These
improvementsresultfromthefineadjustmentofinsulindelivery
provided by closed loop control overnight being superior to a
generallyfixedbasalrateandlesslikelytocausehypoglycaemia.
The first application of closed loop control is therefore likely
tobeinglucoseregulationovernight,astepthathasthepotential
to improve dramatically the safety of insulin delivery during
crucial, generally unsupervised, periods.
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